ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

Considering Alternatives to CAR-T in R/R DLBCL

Julio Chavez

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

Understanding CRISPR and Gene Editing in the Treatment of Heme Malig…

UChicago Medicine

A. Cooper

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta

Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell The…

Stanford Medicine

M. Hamilton

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

Tara Graff

Updates in CAR-T Therapy for Aggressive Lymphomas

Vanderbilt University Medical Center (VUMC)

B. Dholaria

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Total Health

J. Chandler, B. Randolph, M. Onciu

DLBCL: Treatment Options for Transplant-Ineligible Patients

Amit Mehta

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

Optimizing 2L DLBCL Treatment Strategies for CAR-T Ineligible Patien…

Sarah Rutherford

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Moffitt Cancer Center

A. Lazaryan